Reliability of the Galactomannan Enzyme-Linked Immunoassay in Healthy Preterm Infants: A Prospective Cohort Study

J Pediatric Infect Dis Soc. 2023 May 31;12(5):306-307. doi: 10.1093/jpids/piad023.

Authors

Janine Thomann¹, Manuel B Bryant^{1

2}, Vincent D Gaertner¹, Martina Marchesi^{3

4}, Andrea Zbinden⁴, Reinhard Zbinden⁴, Dirk Bassler¹, Christoph M Rüegger¹

Affiliations

¹ Newborn Research, Department of Neonatology, University Hospital and University of Zurich, Zurich, Switzerland.
² Kantonsspital Baden, Department of Pediatrics and Adolescents, Baden, Switzerland.
³ Medica (Medizinische Laboratorien Dr. F. Kaeppeli AG), Zurich, Switzerland.
⁴ Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.

PMID: 37067853
DOI: 10.1093/jpids/piad023

No abstract available

Keywords: Bifidobacterium spp; galactomannan enzyme-linked immunoassay; invasive aspergillosis; preterm infants; probiotics.

MeSH terms

Enzyme-Linked Immunosorbent Assay
Humans
Immunoenzyme Techniques
Infant
Infant, Newborn
Infant, Premature*
Prospective Studies
Reproducibility of Results
Sensitivity and Specificity

Substances

galactomannan